BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

Market Cap	23.19B
Revenue (ttm)	1.18B
Net Income (ttm)	62.08M
Shares Out	422.74M
EPS (ttm)	0.15
PE Ratio	373.52
Forward PE	88.47
Dividend	0.10 (0.18%)
Ex-Dividend Date	Jun 23, 2025

Volume	4,776,661
Average Volume	9,909,211
Open	54.98
Previous Close	54.85
Day's Range	52.78 - 54.98
52-Week Range	28.45 - 122.59
Beta	0.20
RSI	41.03
Earnings Date	Oct 31, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 1,151
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688166

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 189.17 million, a decrease of -6.57%.